The role of nitric oxide and cytokines in heart failure

Coronary Artery Disease

Volumn 8, Issue 6, 1997, Pages 389-401

  Birks, Emma J ^a   Yacoub, Magdi H ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TUMOR NECROSIS FACTOR ALPHA;

ENDOCARDIUM; HEART FAILURE; HEART MUSCLE CELL; HUMAN; INFLAMMATION; INOTROPISM; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

EID: 0030822135     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019501-199706000-00007     Document Type: Review

References (135)

1. Schocken DD, Arrieta MI, Leaverton PE: Prevalence and mortality rate of congestive heart failure In the United States. J Am Coll Cardiol 1992, 20:301-306.
2. Kannel WB, Ho K, Thorn T: Changing epidemiological features of cardiac failure. Br Heart J 1994, 72 (suppl):S3-S9.
3. Chatterjee K: Heart failure therapy in evolution [editorial]. Circulation 1996, 94:2689-2693.
4. Taylor SH: Congestive heart failure. Towards a comprehensive treatment Eut Heart J 1996, 17 (suppl B):43-56.
5. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJJ, Cuddy TE, et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992, 327:669-677.
6. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685-691.
7. The Consensus Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study. N Engl J Med 1987, 316:1429-1435.
8. Bristow MR, Gilbert EM: Improvement in cardiac myocyte function by biological effects of medical therapy: A new concept in the treatment of heart failure. Eur Heart J 1995, 16 (suppl F):20-31.
9. Davies CH, Harding SE, Poole-Wilson PA: Cellular mechanisms of contractile dysfunction in human heart failure. Eur Heart J 1996, 17:189-198.
10. Packer M:Evolution of the neurochormonal hypothesis to explain the progression of chronic heart failure. Eur Heart J 1995, 16 (suppl F):4-6.
11. Moncada S, Palmer RM, Higgs EA: Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991, 43:109-142.
12. Kelly RA, Balligand JL, Smith T: Nitric oxide and cardiac function. Circ Res 1996, 79:363-380. An excellent and thorough review of the physiology and synthesis of NO, concentrating on its effects on cardiac function.
13. Welch G, Loscalzo J: Nitric oxide and the cardiovascular system. J Cardiac Surg 1994, 74:1121-1125.
14. Loscalzo J, Welch G: Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 1995, 38:87-104. A useful review of the physiological effects of NO in the cardiovascular system.
15. Goretski J, Hollocher TC: Trapping of nitric oxide produced during denitrification by extracellular haemoglobin. J Biol Chem 1988, 263:2316-2323.
16. Ignarro LJ, Fukoto JM, Griscavage JM, Rogers NE, Byrnes RE: Oxidation of nitric oxide in aqueous solution to nitrite but not nitrate: Comparison with enzymatically formed nitric oxide from L-arginine. Proc Natl Acad Sci U S A 1993, 90:8103-8107.
17. Wennmalm A, Benthin G, Petersson AS: Dependence of the metabolism of nitric oxide (NO) in healthy human whole blood on the oxygenation of its red cell haemoglobin. Br J Pharmacol 1992, 106:507-508.
18. Ignarro LI: Signal transduction mechanisms involving nitric oxide. Biochem Pharmacol 1991, 41:485-490.
19. Salvemmi D, Misko TP, Masferrer JL, Seibert K, Currie MG, Needleman P: Nitric oxide activates cyclo-oxygenase enzymes. Proc Natl Acad Sci U S A 1993, 90:7240-7244.
20. Corbett JA, Kwon G, Turk J, McDaniel L: IL-1β induces the coexpression of both nitric oxide synthase and cyclooxygenase by the islets of Langerhans: Activation of cyclooxygenase by nitric oxide. Biochem J 1993, 32:13767-13770.
21. Wink DA, Osawa Y, Darbyshire JF, Jones CR, Eshenaus SC, Nims RW: Inhibition of cytochromes P-450 by nitric oxide and a nitric oxide releasing agent Arch Biochem Biophys 300:115-123.
22. Clancy RM, Leszczynska-Piziak J, Abramson SB: Nitric oxide, an endothelial relaxing factor, inhibits neutrophil Superoxide anion production via a direct action on the NADPH oxidase. J Clin Invest 1992, 90:1116-1121.
23. Beckman JS, Beckman TW, Chen J, Marshall PA, Freedman BA: Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and Superoxide. Proc Natl Acad Sci U S A 1990. 87:1620-1624.
24. Wright DT, Cohn LA, Li H, Fischer B, Li CM, Alder KB: Interactions of oxygen radicals with airway epithelium. Environ Health Perspect 1994, 102 (suppl 10):85-90.
25. Nathan C, Xie QW: Regulation of biosynthesis of nitric oxide. J Biol Chem 1994, 269:13725-13728.
26. Bredt DS, Hwang PM, Glatt CE, Lowenstein C, Reed RR, Snyder SH: Cloned and expressed nitric oxide synthase structurally resembles cytochrome P-450 reductase. Nature 1991, 351:714-718.
27. Su Z, Blazing MA, Fan D, George SE: The calmodulin-nitric oxide synthase interaction: Critical role of the calmodulin latch domain in enzyme activation. J Biol Chem 1995, 270:29117-29122.
28. Abdu-Soud HM, Feldman PL, Clark P, Steuhr DJ: Electron transfer in the nitric oxide syntheses: Characterization of L-arginine analogs that block heme iron reduction. J Biol Chem 1994, 269:32318-32326.
29. Abdu-Soud HM, Lottus M, Steuhr DJ: Subunit dissociation and unfolding of macrophage NO synthase: Relationship between enzyme structure, prosthetic group binding, and catalytic function. Biochemistry 1995, 34:11167-11175.
30. Griffith OW, Stuer DJ: Nitric oxide synthases: Properties and catalytic mechanism. Annu Rev Physiol 1995, 57:707-736.
31. Knowles RG, Moncada S: Nitric oxide synthases in mammals. Biochem J 1994, 298:249-258.
32. Snyder SH: NO endothelial NO. Nature 1995, 377:196-197.
33. Marsden PA, Heng HHQ, Scherer SW, Stewaet RJ, Hall AV, Shi XM, et al.: Structure and chromosomal localisation of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993, 268:17478-17488.
34. Dinnerman JL, Lowenstein CJ, Snyder SH: Molecular mechanisms of nitric oxide regulation. Circ Res 1993, 73:217-222.
35. Venema RC, Sayegh HS, Kent JD, Harrison DG: Identification. characterisation and comparison of the calmodulin-binding domains of the endothelial and inducible nitric oxide synthases. J Biol Chem 1996, 271:6435-6440.
36. Ignarro LJ: Biological actions and properties of endothelium-derived nitric oxide formed and released from artery and vein. Circ Res 1989, 65:1-21.
37. Amrani M, O'Shea J, Allen NJ, Harding SE, Jajakumar J, Pepper JR, Moncada S, Yacoub MH: Role of basal release of nitric oxide on coronary flow and mechanical performance of the isolated rat heart J Physiol Lond 1992, 456:681-687.
38. Ursell PC, Mayes M: Anatomic distribution of nitric oxide synthase in the heart Int J Cardiol 1995, 50:217-223. The distribution of the NO synthases in the heart is summarized.
39. Sosunov AA, Hassall CJS, Loesch A, Turmaine M, Burnstock G: Nitric oxide synthase containing neurones and nerve fibres within cardiac ganglia of rat and guinea pig: An electron-microscopic immunocyto- Chemical study. Cell Tissue Res 1996, 284:19-28.
40. Taneka K, Chiba T: Nitric oxide synthase containing neurones in the atrioventricular node of the guinea pig heart J Auton Neur Syst 1995, 51:245-253.
41. Klimaschewski ZL, Kumer W, Mayer B, Couranel JY, Preissler U, Philippin B, Heyn L: Nitric oxide synthase in cardiac nerve fibres and neurones of rat and guinea pig heart. Circ Res 1992, 71:533-537.
42. Kobzik L, Reid MB, Bredt PS, Stamler JS: Nitric oxide in skeletal muscle. Nature 1994, 372:546-548.
43. Balligand JL, Kobzik L, Man X, Kaye PM, Belhassen L, O'Hara PS, Kelly RA, Smith TW, Michel T: Nitric oxide-dependent parasympathetic signalling is due to activation of constitutive endothelial (type III) nitric oxide synthase in cardiac myocytes. J Biol Chem 1995, 270:14582-14586.
44. Scwarz P, Diem R, Dun NJ, Forstermann V: Endogenous and exogenous nitric oxide inhibits noradrenaline release from rat heart sympathetic nerves. Circ Res 1995, 77:841-848.
45. Kaye DM, Wiviett SD, Balligand JL, Smith TW: Nitric oxide inhibits norepinephrine uptake into cardiac sympathetic neurons. Circulation 1995, 92 (suppl 1):507.
46. 2+ current adult rat rabbit atrio-ventricular nodal cells. Circ Res 1996, 78:998-1006.
47. Amrani M, Goodwin AT, Gray CC, Yacoub MH: Ageing is associated with reduced basal and stimulated release of nitric oxide by the coronary endothelium. Acta Physiol Scand 1996, 157:79-84.
48. Marsden, PA, Heng HH, Shui XM, Tui LC, Hall AV: Localisation of the human gene nitric oxide synthase (NOS 2) to chromosome 17q11.2qlz. Genomics 1994, 19:183-185.
49. Xie QW, Chou HJ, Calaycay J, Mumford RA, Swiderek KM, Lee TO, et al.: Cloning and characterisation of inducible nitric oxide synthase from mouse macrophages. Science 1992, 256:225-228
50. Moilanen E, Vapaatalo H: Nitric oxide in inflammation and immune response. Ann Med 1995, 27:359-367
51. Kanno K, Hirata Y, Imai T, Marumo F: Induction of nitric oxide synthase gene by interleukin in vascular smooth muscle cells. Hypertension 1993, 22:34-39.
52. Hamid Q, Springall DR, Rivieros-Moreno V, Chanez P, Howarth P, Reddington A, et al: Induction of nitric oxide synthase in asthma. Lancet 1993, 342:1510-1513.
53. 2+-independent nitric oxide synthase in the myocardium. Br J Pharmacol 1992, 105:575-580.
54. Balligand JL, Ungureanu-Longrois D, Simmons WW, Pimental D, Malinski TA, Kapturczak M, et al.: Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes: Characterisation and regulation of iNOS expression and detection of iNOS activity in single cardiac myocytes in vitro. J Biol Chem 1994, 269:27580-27588.
55. Balligand JL, Ungureanu-Longrois D, Simmons WW, Kobzik L, Lowenstein CJ, Lamas S, Kelly RA, Smith TW, Michel T: Induction of NO synthase in rat cardiac microvascular endothelial cells by IL-1β and IFN-gamma. Am J Physiol 1995, 268:H1293-H1303.
56. Worrall NK, Lazenby WD, Misko TP, Lin TS, Rodi CP, Manning PT, Tilton RG, Williamson JR, Ferguson TB: Modulation of in vivo alloreactivity by inhibition of inducible nitric oxide synthase. J Exp Med 1995, 181:63-70.
57. Yang X, Chowddhury N, Cai B, Brett J, Marboe C, Sciacca, Michler RE, Cannon PJ: Induction of myocardial nitric oxide synthase by cardiac allograft rejection. J Clin Invest 1994, 94:714-721.
58. Brady AJB, Poole-Wilson PA, Hardin SE, Warren JB: Nitricoxide production within cardiac myocytes reduces their contractility in endotoxemia. Am J Physiol 1992, 263:H1963-H1966.
59. 2+)l and cell contraction in cultured chick ventricular myocytes. Circ Res 1994, 75:285-295.
60. Tsujino M, Hirata Y, Imai T, Kanno K, Eguchi S, Ito H, Marumo F: Induction of nitric oxide synthase gene by interleukin-1β in cultured rat cardiocytes. Circulation 1994, 90:375-383.
61. Ungureanu-Longrois D, Balligand JL, Simmons WW, Okada I, Kobzik L, Lowenstein CJ, Kunkel SU, Michel T, Kelly RA, Smith TW: Induction of nitric oxide synthase activity by cytokines in ventricular myocytes is necessary but not sufficient to decrease contractile responsiveness to β-adrenergic agonists. Circ Res 1995, 77:494-502.
62. L-NMMA. on cardiac myocytes. Biochem Biophys Res Commun 1994, 205:992-997.
63. Shindo T, Ikeda U, Ohkawa F, Kawahara Y, Yokoyama M, Shimada K: Nitric oxide synthesis in cardiac myocytes and fibroblasts by inflammatory cytokines. Cardiovasc Res 1995, 29:813-819.
64. De Vera ME, Shapiro RA, Nussler AK, Mudget JS, Simmons RL, Morris SM Jr, Billial TR, Geller DA: Transcriptional regulation of human inducible nitric oxide synthase (INOS) gene by cytokines: Initial analysis of the human iNOS promoter. Proc Natl Acad Sci U S A 1996, 93:1054-1059.
65. Singh K, Balligand JL, Fischer TA, Smith TW, Kelly RA: Regulation of cytokine-inducible nitric oxide synthase in cardiac myocytes and microvascular endothelial cells: Role of extracellular signal-regulated kinasesl and 2(ERKI/ERK2) and STAT1-alpha. J Biol Chem 1996, 271:1-7.
66. Ikeda U, Maeda Y, Kawahara Y, Yokoyama M, Shimada K: Angiotensin II augments cytokine-stimulated nitric oxide synthesis in rat cardiac myocytes. Circulation 1995, 92:2683-2689.
67. Ikeda U, Murakami Y, Kanbe T, Shimada K: Alpha-adrenergic stimulation enhances nitric oxide synthase expression in rat cardiac myocytes. J Moll Cell Cardiol 1996, 28:789-795.
68. Oddis CV, Simmons RL, Hattler BG, Finkel MS: CAMP enhances inducible nitric oxide mRNA stability in cardiac myocytes. Am J Physiol 1995, 269:H2044-H2050.
69. Ikeda U, Yamamoto K, Ichida M, Ohkawa F, Murata M, Iimura O, Kusano E, Asano Y, Shimada K: Cyclic AM P augments cytokine-stimulated nitric oxide synthesis in rat cardiac myocytes. J Moll Cell Cardiol 1996, 28:789-795.
70. Roberts AB, Vodovotz Y, Roche NS, Sporn MB, Nathan CF: Role of nitric oxide in antagonistic effects of transforming growth factor-beta and interleukin-1 on the beating rate of cultured cardiac myocytes. Mol Endocrinol 1992, 6:1921.
71. Simmons WW, Closs EI, Cunningham JM, Smith TW, Kelly RA: Cytokines and insulin induce cationic amino acid transporter expression in cardiac myocytes: Regulation of L-arginine transport and NO production by CAT-1, CAT-2A and CAT-2B. J Biol Chem 1996, 271:11694-11702.
72. Brady AJB, Warren JB, Poole-Wilson PA, Williams TJ, Harding SE: Nitric oxide attenuates cardiac myocyte contraction. Am J Physiol 1993, 265: H176-H182.
73. Shulz R, Panas DL, Catena R, Moncada S, Olley PM, Lopaschuk GD: The role of nitric oxide in cardiac depression induced by interleukin-1β and tumour necrosis factor-alpha. Br J Pharmacol 1995, 114:27-34.
74. Evans HG, Lewis MJ, Shah AM: Lnterleukin-1β modulates myocardial contraction via dexamethasone-sensitive production of nitric oxide. Cardiovasc Res 1993, 27:1486-1490.
75. Tao S, McKenna TM: In vitro endotoxin exposure induces contractile dysfunction in adult rat cardiac myocytes. Am J Physiol 1994, 267: H1745-H1752.
76. Gardiner SM, Kemp PA, March JE, Bennett T: Cardiac and regional haemodynamics, inducible nitric oxide synthase (NOS) activity, and the effects of NOS inhibitors in conscious, endotoxaemic rats. Br J Pharmacol 1995, 116:2005-2016.
77. Paulus WJ, Vantrimpont PJ, Shah AM: Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Assessment by bicoronary sodium nitroprusside infusion. Circulation 1994, 89:2070-2078.
78. Grocott-Mason R, Fort S, Lewis MJ, Shah AM: Myocardial relaxant effect of exogenous nitric oxide in isolated ejecting hearts. Am J Physiol 1994, 266:H1699-H1705.
79. Colucci WS, Denniss AR, Leatherman GF, Quigg RJ, Ludmer PL, Marsh JD, Gauthier D: Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure: Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition. J Clin Invest 1988, 81:1103-1110.
80. Colucci WS, Ribeiro JP, Rocco MB, Quigg RJ, Creager MA, Marsh JD, Gauthier DF Hartley LH: Impaired chronotropic response to exercise in patients with congestive heart failure: Role of post-synaptic β-adrenergic desensitisation. Circulation 1989, 80:314-323.
81. Balligand JL, Ungureanu D, Kelly RA, Kobzik L, Pimental D, Michel T, Smith TW: Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest 1993, 91:2314-2319.
82. Yamamoto S, Tsutsui H, Tagawa H, Saito K, Takahashi M, Tada H, Yamamoto M, Katoh M, Egashira K, Takeshita A: Role of myocyte nitric oxide in β-adrenergic hyporesponsiveness in heart failure. Circulation 1997, 95:1111-1114.
83. Hare JM, Keaney JF Jr, Kelly RA, et al.: Inhibition of nitric oxide synthase potentiates the positive inotropic response to β-adrenergic stimulation in normal dogs. Circulation 1993, 88 (suppl 1):1905.
84. L-N-monomethylarginine.
85. Chung MK, Gulik TS, Rotondo RE, Schreiner GF, Lange LG: Mechanism of cytokine inhibition of β-adrenergic agonist stimulation of cyclic AMP in rat cardiac myocytes. Impairment of signal transduction. Circ Res 1990, 67:753-763.
86. Lewis NP, Tsao PS, Rickenbacher PR, Xue C, Johns RA, Haywood G, et al.: Induction of nitric oxide synthase in the human cardiac allograft is associated with contractile dysfunction of the left ventricle. Circulation 1996, 93:720-729. The authors investigated inducible NO synthase expression in myocardial biopsies after transplantation and found that, although it did not correlate with rejection, it did correlate with episodes of myocardial dysfunction.
87. Decking UKM, Flesche CW, Godecke A, Schrader J: Endotoxin-induced contractile dysfunction in guinea pig hearts is not mediated by nitric oxide. Am J Physiol 1995, 268:H2460-H2465.
88. Balligand JL, Kelly RA, Marsden PA, Smith TW, Michel T: Control of cardiac muscle cell function by an endogenous nitric oxide signalling system. Proc Wart Acad Sci U S A 1993, 90:347-351.
89. Hare JM, Colucci WS: Role of nitric oxide in the regulation of myocardial function. Prog Cardiovasc Dis 1995, 38:155-166. A review of the evidence for a role for NO in the regulation of myocardial function.
90. Pinsky DJ, Cai B, Yang X, Rodnguez C, Siacca RR, Cannon PJ: The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor β. J Clin Invest 1995, 95:677-685.
91. Albina JE, Cui S, Mateo RB, Reichner JS: Nitric oxide mediated apoptosis in murine peritoneal macrophages. J Immune 1993, 150:5080-5085.
92. Cui S, Reichner JS, Mateo RB, Albina JE: Activated murine macrophages induce apoptosis in tumour cells through nitric oxide-dependent or independent mechanisms. Cancer Res 1994, 54:2462-2467.
93. Shimaoka M, Iida T, Ohara A, Tanaka N, Mashimo T, Honda T, Yoshiya I: NOC, a nitric-oxide-releasing compound, induced dose-dependent apoptosis in macrophages. Biochem Biophys Res Commun 1995, 209: 519-526.
94. Messmer UK, Lapetina EG, Brune B: Nitric oxide-induced apoptosis in Raw 264.7 macrophages is antagonised by protein kinase C- and protein kinase A-activating compounds. Mol Pharmacol 1995, 47:757-765.
95. Pinsky DJ, Yang Y, Aji W, Szabolcs M, Liao H, Sciacca RR, Cannon PJ: Nitric oxide induces apoptosis of adult rat cardiac myocytes. Circulation 1995, 92 (suppl 1):565.
96. Gulick T, Pieper SJ, Murphy MA, Lange LG, Schreiner GF: A new method for assessment of cultured cardiac myocyte contractility detects immune factor-mediated inhibition of β-adrenergic responses. Circulation 1991, 84:313-321.
97. Klabunde RE, Ritger RC, Helgren MC: Cardiovascular actions of inhibitors of endothelium-derived relaxing factor (nitric oxide) formation/release in anaesthetised dogs. Eur J Pharmacol 1991, 199:51-59.
98. L-arginine methyl ester in conscious rats. In Biology of nitric oxide. Edited by Moncada S, Marietta MA, Hibbs JB, Higgs EA. London: Portland; 1992:23-26.
99. Reid IA, Bui H, Chou L: Role of nitric oxide in the renin and heart rate response to β-adrenergic stimulation. Hypertension 1994, 23 (suppl 11:49-53.
100. Stamler JS, Loh E, Roddy MA, Currie KE, Greager MA: Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation 1994, 89:2035-2040.
101. Winlaw CS, Smythe GA, Keogh AM, Schyvens CG, Spratt PM, Macdonald P: Increased nitric oxide production in heart failure. Lancet 1994, 344:373-374.
102. De Belder AJ, Radomski MW, Why HJF, Richardson PJ, Bucknall CA, Salas E, Martin JF, Moncada S: Nitric oxide synthase activities in human myocardium. Lancet 1993, 341:84-85.
103. Habib FM, Springall DR, Davies GJ, Oakley CM, Yacoub MH, Polak JM: Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 1996, 347:1151-1155. Strong inducible NO synthase staining was found in the cardiac myocytes of patients with dilated cardiomyopathy by immunocytochemistry, with weaker staining in the myocytes of patients with ischaemic heart disease. Moderate inducible NO synthase staining was seen in the endothelium and smooth muscle cells of blood vessels in patients with either disease. TNF-α staining was seen in the myocytes of patients with dilated cardiomyopathy, in a similar distribution to the inducible NO synthase staining. TNF-α was also seen in the endothelium and smooth muscle cells of blood vessels but not in patients with ischaemic heart disease.
104. Vejlstrup NG, Bouloumie A, Andersen CB, Boesgaard S, Mortensen SA, Busse R, Aldershvile J: Expression of the inducible nitric oxide synthase (iNOS) in heart failure patients with dilated cardiomyopathy and ischaemic heart disease. Circulation 1996, 94 (suppl 1):29.
105. Haywood GA, Tsao PS, Von der Leyen HE, Mann MJ, Keeling PJ, Trindale PT, et al.: Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996, 93:1087-1094. Inducible NO synthase messenger RNA was detected in the myocardium of patients with heart failure and paralleled the expression of atrial natriuretic peptide.
106. De Beider AJ, Radomski MW, Why HJ, Richardson PJ, Martin JF: Myocardial calcium-independent nitric oxide synthase activity is present in dilated cardiomyopathy, myocarditis, and postpartum cardiomyopathy but not in ischaemic or valvular heart disease. Br Heart J 1995, 74:426-430.
107. Drexler H, Kastner S, Strobel A, Studer R, Brodde OE, Hasenful G: Expression, activity and functional significance of endothelial and inducible nitric oxide synthase in the failing human heart Circulation 1996, 94(supp 1):29.
108. Szalbolocs M, Michler RE, Yang X, Aji W, Roy D, Athan E, Sciacca RR, Minanov OP, Cannon PJ: Apoptosis of cardiac myocytes during cardiac allograft rejection: Relation to induction of nitric oxide synthase. Circulation 1996, 94:1665-1673. Apoptosis of myocardial cells was detected during rejection of rat cardiac allografts. Apoptosis paralleled inducible NO synthase expression, suggesting that apoptosis may be triggered by NO.
109. Sharov RG, Sabbab HN, Shimoyama H, Gousseu AV, Lesen M, Goldstein S: Evidence of cardiocyte apoptosis in myocardium of dogs with chronic heart failure. Am J Pathol 1996, 148:141-149.
110. Feuerstein GZ, Yue TL: Apoptosis and the heart Br Appl Myol 1996, 6:221-225.
111. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ, Schmidt U, Semigran MJ, Dec GW, Khaw BA: Apoptosis in myocytes in end-stage heart failure. W Engl J Med 1996, 335:1182-1189.
112. Smith CJ, Sun D, Hoegler C, Roth BS, Zhang X, Zhao G, et al.: Reduced gene expression of vascular endothelial NO synthase and cyclooxygenase in heart failure. Circ Res 1996, 78:58-64.
113. Yoshizumi M, Perrella MA, Burnett JC, Lee ME: Tumour necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993, 73:205-209.
114. Forstermann U, Kuk JE, Nakane M, Pollok JS: The expression of endothelial nitric oxide synthase is downregulated by tumour necrosis factor alpha (TNF-alpha). Naunyn Schmeideoergs Arch Pharmacol 1993, 347:R61.
115. Reiling NB, Ulmer AJ, Duchrow M, Enust M, Fled HD, Hanschild S: Nitric oxide synthase mRNA. Expression of different isoforms inhuman monocytes/macrophages. Eut J Immunol 1994, 24:1941-1944.
116. Oral H, Kapadia S, Nakano M, Torre-Amione G, Lee J, Lee-Jackson D, Young JB, Mann DL: Tumour necrosis factor-alpha and the failing human heart. Clin Cardiol 1995, 18 (suppl IV):120-127.
117. Levine B, Kalman J, Mayer L, Fillit HM, Packer M: Elevated circulating levels of tumour necrosis factor in severe chronic heart failure. N Engt J Med 1990, 323:236-241.
118. Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL: Cellular basis for the negative inotropic effects of tumour necrosis factor-alpha in the adult mammalian heart J Clin Invest 1993, 92:2303-2312.
119. Torre-Amione G, Kapiada S, Benedict C, Oral H, Young J, Mann DL: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 1996, 27:1201-1206. TNF-α and IL-6 levels were analysed in patients with New York Heart Association class I-III heart failure. Plasma TNF levels were elevated in patients with heart failure, compared with controls, and levels increased with increasing class of heart failure. IL-6 levels were also elevated in patients with heart failure and were progressively elevated in relation to the decreasing functional status of the patient.
120. Malsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S: Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994, 72:561-566.
121. Dutka DP, Elborn JS, Delamere F, Shale DJ, Morris GK: Tumour necrosis factor-alpha in severe congestive cardiac failure. Br Heart J 1993, 70:141-143.
122. McMurray J, Abdullah I, Dargie HJ, Shapiro D: Increased concentrations of tumour necrosis factor in 'cachectic' patients with severe chronic heart failure. Br Heart J 1991, 66:356-358.
123. Milani RV, Mehra MR, Endres S, Eigler A, Cooper ES, Lavie CJ, Ventura HO: The clinical relevance of circulating tumour necrosis factor-alpha in acute decompensated chronic heart failure without cachexia. Chest 1996, 110:992-995.
124. Doyama K, Fujiwara H, Fukumoto M, Tanaka M, Fujiwara Y, Oda T, et al.: Tumour necrosis factor is expressed in cardiac tissue of patients with heart failure. Int J Cardiol 1996, 54:21 7-225.
125. Torre-Amione GT, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL: Expression and functional significance of tumour necrosis factor receptors in human myocardium. Circulation 1995, 92:1487-1493.
126. Weidermann CJ, Beimpold H, Herald M, Knapp E, Braunsteiner H: Increased levels of serum neopterin and decreased production of neutrophil Superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha. J Am Coll Cardiol 1993, 22:1897-1901.
127. Fuchs D, Weiss G, Reibnegger G, Wachter H: The role of neopterin as a monitor of cellular immune activation in transplantation, inflammatory, infectious, and malignant diseases. Crit Rev Clin Lab Sci 1992, 29:307-341.
128. Gross SS, Levi R: Tetrahydrobiopterin synthesis. An absolute requirement for cytokine-induced nitric oxide generation by vascular smooth muscle. J Biol Chem 1992, 267:25722-25729.
129. Satoh M, Nakamura M, Tamura G, Segawa I, Tashiro A, Satodate R: Inducible nitric oxide synthase and tumour necrosis factor alpha in the myocardium in dilated cardiomyopathy. Circulation 1996, 94 (suppl 1):348.
130. Ferrari R, Comini L, Bachetti T, Agnoletti L, Gaia G, Milanesi B, et al.: Tumour necrosis factor and expression of inducible NO-synthase in the monocytes of patients with congestive heart failure. Circulation 1996, 94 (suppl 1):468.
131. Clemens MJ: Cytokines. London: Bios Scientific: 1994:1997.
132. Munger MA, Johnson BJ, Amber U, Callahan KS, Gilbert EM: Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischaemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1996, 77:723-727.
133. MacGowan GA, Douglas LM, Kormas RL, Feldman AM, Murali S: Clinical correlations of circulating interleukin-6 in severe heart failure. Circulation 1996, 94 (suppl 1):329.
134. Tsutamoto T, HisanagaT, Wada A, Maeda K, Maeda Y, Fukai D, Ohnishi M, Sugimoto Y, Kinoshita M: Interleukin-6 production in peripheral circulation increases with the severity of heart failure and the increase of plasma interleukin-6 level has an important role on the prognosis of patients with congestive heart failure. Circulation 1996, 94 (suppl 1):495. IL-6 levels were negatively correlated with left ventricular ejection fraction, and, out of ejection fraction, New York Heart Association class, plasma noradrenaline level, and IL-6 level, only a high IL-6 level was an independent prognostic indicator in these patients.
135. Lommi J, Koskinen P, Naveri H, Leinonen H, Pulkki K, Kupari M: Circulating ineterleukin-6 concentrations in relation to central haemodynamics in cardiac patients [abstract]. Eur Heart. J 1996, 17 (suppl):446.